[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Michelle Gilson Biography and Net Worth

CFO of Arcellx

Michelle Gilson joined Arcellx, Inc. as our chief financial officer in May 2022. Most recently, Ms. Gilson served as a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, covering biotechnology companies. Prior to joining Canaccord, Ms. Gilson held biotechnology equity research roles at Jefferies, LLC; Instinet, LLC (Nomura Securities); Oppenheimer & Co. Inc.; and Goldman Sachs. Ms. Gilson earned her B.S. in Business Administration from the University of Southern California.

What is Michelle Gilson's net worth?: The estimated net worth of Michelle Gilson is at least $639,637.50 as of September 17th, 2024. Ms. Gilson owns 6,915 shares of Arcellx stock worth more than $639,638 as of December 3rd. This net worth evaluation does not reflect any other assets that Ms. Gilson may own. Additionally, Ms. Gilson receives a salary of $602,800.00 as CFO at Arcellx. Learn More about Michelle Gilson's net worth.
How old is Michelle Gilson?: Ms. Gilson is currently 31 years old. There are 5 older executives and no younger executives at Arcellx. The oldest executive at Arcellx is Mr. David Tice Ph.D., Chief Scientific Officer, who is 53 years old. Learn More on Michelle Gilson's age.
What is Michelle Gilson's salary?: As the CFO of Arcellx, Inc., Ms. Gilson earns $602,800.00 per year. There are 2 executives that earn more than Ms. Gilson. The highest earning executive at Arcellx is Mr. Rami Elghandour, Chairman and Chief Executive Officer, who commands a salary of $941,670.00 per year. Learn More on Michelle Gilson's salary.
How do I contact Michelle Gilson?: The corporate mailing address for Ms. Gilson and other Arcellx executives is , , . Arcellx can also be reached via phone at 240-327-0603 and via email at [email protected]. Learn More on Michelle Gilson's contact information.
Has Michelle Gilson been buying or selling shares of Arcellx?: Michelle Gilson has not been actively trading shares of Arcellx in the last ninety days. Most recently, Michelle Gilson sold 15,000 shares of the business's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $77.73, for a transaction totalling $1,165,950.00. Following the completion of the sale, the chief financial officer now directly owns 6,915 shares of the company's stock, valued at $537,502.95. Learn More on Michelle Gilson's trading history.
Who are Arcellx's active insiders?: Arcellx's insider roster includes Jill Carroll (Director), Rami Elghandour (Chairman and Chief Executive Officer), Michelle Gilson (CFO), Christopher Heery (Chief Medical Officer), Kavita Patel (Director), Olivia Ware (Director), and Olivia Ware (Director). Learn More on Arcellx's active insiders.
Are insiders buying or selling shares of Arcellx?: In the last year, insiders at the sold shares 29 times. They sold a total of 852,221 shares worth more than $59,596,182.56. The most recent insider tranaction occured on November, 11th when Director Kavita Patel sold 15,238 shares worth more than $1,614,008.96. Insiders at Arcellx own 6.2% of the company. Learn More about insider trades at Arcellx.
Information on this page was last updated on 11/11/2024.

Michelle Gilson Insider Trading History at Arcellx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/17/2024	Sell	15,000	$77.73	$1,165,950.00	6,915
6/26/2024	Sell	12,877	$53.70	$691,494.90	6,915
5/24/2024	Sell	12,121	$50.71	$614,655.91	19,792
3/18/2024	Sell	6,825	$69.34	$473,245.50	9,485
1/4/2024	Sell	8,514	$55.27	$470,568.78	16,310
5/24/2023	Sell	8,704	$42.46	$369,571.84	15,485

Michelle Gilson Buying and Selling Activity at Arcellx

Arcellx Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $92.50

$92.04

$96.39

50 Day Range

MA: $88.27

$76.07

$106.53

2 Week Range

Now: $92.50

$46.42

$107.37

Volume

181,796 shs

Average Volume

477,104 shs

Market Capitalization

$5.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

Michelle Gilson Biography and Net Worth

What is Michelle Gilson's net worth?

How old is Michelle Gilson?

What is Michelle Gilson's salary?

How do I contact Michelle Gilson?

Has Michelle Gilson been buying or selling shares of Arcellx?

Who are Arcellx's active insiders?

Are insiders buying or selling shares of Arcellx?